Zacks Investment Research on MSN
QURE stock crashes 32% in a week: Here's what you should know
Shares of uniQure N.V. QURE plunged 31.8% in a week, primarily after the company announced a disappointing regulatory update ...
uniQure N.V. (NASDAQ:QURE) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 8, RBC Capital reiterated a Buy rating on uniQure N.V. (NASDAQ:QURE) and increased its price target ...
UniQure (QURE) surged over 250% today and almost crossed $50 after the company released Phase 1/2 data for AMT-130, which is its experimental gene therapy for Huntington’s disease. The dose showed ...
UniQure (NASDAQ:QURE) is one of the best small cap stocks to buy with huge upside potential. Stifel slashed the price target on UniQure (NASDAQ:QURE) to $40 from $50 on December 11, keeping a Buy ...
uniQure's AMT-130 gene therapy for Huntington’s Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen ...
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. UniQure's Pivotal Study design, including the comparison of the Pivotal Study to the ENROLL-HD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results